BONEJOA Injection (Ibandronic Acid Sodium Monohydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
White Life Science Co., Ltd.
MFDS item code 201700825 · Notified 2017.02.15 · Insurance code 625201711
Treatment of osteoporosis in postmenopausal women
This drug is used to treat osteoporosis that may occur in postmenopausal women. Osteoporosis is a condition where bones become weak and are at high risk of fractures. This drug helps increase bone density and reduce fracture risk, thus maintaining healthy bones. It effectively protects bone health in postmenopausal women and prevents fractures. Therefore, it is used for the treatment of postmenopausal osteoporosis.
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary for patients with mild or moderate renal impairment who have a serum creatinine of 200 µmol/L(2.3mg/dL) or lower or a creatinine clearance of 30ml/min or higher. Administration of this medicine is not recommended for patients with a serum creatinine exceeding 200 µmol/L(2.3mg/dL) or a creatinine clearance below 30ml/min, as clinical experience is insufficient. Elderly: No dose adjustment is necessary.
Efficacy and safety in children 18 years of age or younger have not been studied.
This drug must be administered as an intravenous injection, and caution should be exercised as improper administration around arteries or veins may cause tissue damage. It should not be used in patients with hypersensitivity to this drug or untreated hypocalcemia. During the use of this drug, gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation may appear. Musculoskeletal symptoms such as myalgia, arthralgia, and musculoskeletal pain have also been reported. In some patients, influenza-like symptoms may occur, which include fever, chills, fatigue, and arthralgia, usually mild and temporary. Adverse effects related to the nervous system and skin, such as headache, rash, and fatigue, may also occur. Long-term use of this drug has been rarely associated with serious bone-related side effects such as osteonecrosis of the jaw or external auditory canal, thus oral hygiene and dental care should be prioritized. During osteoporosis treatment, muscle, joint, and bone pain may worsen; should these symptoms occur, consult with healthcare professionals. If pain in the thigh or groin is present, consider the possibility of atypical femoral fractures and further examination is needed. In cases of pregnancy or breastfeeding, the safety of this drug is not established and should be avoided. As this drug is excreted through the kidneys, patients with renal impairment need regular monitoring. In cases of overdose, there may be a burden on the kidneys and liver, requiring careful monitoring, and appropriate treatment is necessary if hypocalcemia occurs. This drug should not be mixed with solutions that contain calcium and must be administered only by intravenous injection. Do not reuse needles and syringes; safely dispose of them after use. While the potential for interaction with other drugs during the use of this drug is low, it is recommended to consult with a physician or pharmacist.
Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial edema, swelling, hives, uveitis, episkleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical subtrochanteric and iliac femoral fracture, atypical iliac fracture, osteonecrosis of the jaw and external auditory canal, dizziness, optic nerve atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disorders, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, acute renal failure
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a sealed container to prevent air or moisture from entering, ideally at room temperature between 1 degree and 30 degrees Celsius. This helps maintain the effectiveness of the drug and prevents deterioration.
The injection is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, which comes with a single-use needle.
3ml x 1 vial
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
White Life Science Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.